Physician profile
Roy L Bishop
NPI 1669424651
$5,547.43
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $1,258 · 2021: $2,140 · 2022: $841 · 2023: $453 · 2024: $20.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,208.79 | 2020-2023 | Ubrelvy |
| Pfizer INC. | $749.78 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $566.32 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $305.62 | 2019-2023 | Arexvy |
| Novo Nordisk INC | $264.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $257.55 | 2020-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.68 | 2019-2024 | Jardiance |
| Daiichi Sankyo INC. | $209.47 | 2021-2023 | Injectafer |
| Allergan, INC. | $204.99 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $173.60 | 2019-2021 | |
| Amarin Pharma, INC. | $154.96 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $146.98 | 2021 | |
| Lilly USA, LLC | $141.87 | 2019-2023 | Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.85 | 2019-2021 | |
| Eisai INC. | $98.96 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $85.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.06 | 2020-2021 | |
| Abbott Laboratories | $68.33 | 2022-2023 | Freestyle Libre 2 |
| Amgen INC. | $65.97 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $56.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.76 | 2019 | |
| Upsher-Smith Laboratories LLC | $40.14 | 2021 | |
| Zyla Life Sciences, INC. | $39.67 | 2020 | |
| Sanofi Pasteur INC. | $28.01 | 2019-2020 | |
| Corcept Therapeutics | $23.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.90 | 2019 | |
| Exact Sciences Corporation | $20.92 | 2023 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $19.37 | 2021 | |
| Medtronic USA, INC. | $19.03 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.34 | 2021 | |
| Mylan Specialty L.P. | $15.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2021 | |
| Medtronic Minimed, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.